A global call for action to combat antimicrobial resistance: Can we get it right this time? by Mendelson, Marc & Matsoso, Malebona Precious
EDITORIAL
478       July 2014, Vol. 104, No. 7
On 17 May 2014, the World Health Assembly 
adopted World Health Organization (WHO) reso­
lution WHA67.25 ‘Combating antimicrobial resis­
tance including antibiotic resistance’.[1] Among 
other directives, the nine­point call to action urges 
member states ‘to develop or strengthen national plans, strategies 
and international collaboration for the containment of antimicrobial 
resistance’. Such calls have been heard before.[2­3] So what is different 
this time, how do we break the mould to ensure that significant 
international change occurs, and how is South Africa (SA) positioning 
itself to respond to the call?
Commonly, a crisis only becomes a crisis when high­income 
countries become threatened and a tipping point is reached where 
a commodity becomes scarce. Bugs travel, and with them come 
antimicrobial resistance (AMR) genes. The global dissemination 
of New Delhi metallo­beta­lactamase­1 (NDM­1)­containing 
Gram­negative bacteria from India,[4] and Klebsiella pneumoniae 
carbapenemase (KPC) from the USA,[5] testifies to the fact that we 
are facing an international problem, capable of affecting all countries 
irrespective of how good their antimicrobial policies to prevent 
resistance are. As such, an international, collaborative approach is 
needed where all nations are involved. To cement this, a sea­change 
in perception is required. The WHO resolution recognises the 
efficacy of an antimicrobial as a global public good, i.e. one that is 
both non­excludable (universal access) and non­rival in consumption 
(will not deplete the efficacy of the drug). The non­rival nature of 
antimicrobial efficacy can only be preserved if we stop perceiving 
antimicrobials as our own private goods, and attend to the main 
drivers of resistance. This is not only relevant to antimicrobials for 
human use, but applies equally to the far greater volume used for 
animal health, agriculture and aquaculture.
While antibacterial resistance is a Darwinian response by bacteria 
to selective pressure exerted by an antibacterial, its main driver is 
inappropriate overuse. This practice spans resource settings, rural 
and urban communities, public and private healthcare, and all types 
of prescribers. Empiric antibacterial prescribing for undifferentiated 
fever commonly lies at the heart of inappropriate use, whether it 
is the child in a rural low­ or middle­income country attending 
a local clinic with what is actually malaria, adults throughout the 
world requesting antibacterials for themselves or their children for 
viral upper respiratory tract infection, or the elderly patient who 
is admitted to hospital with fever and confusion labelled ‘sepsis, 
unknown cause’. Improved diagnostics, preferably at point of care 
and ideally those that identify not only the microbe but its resistance 
profile too, in addition to development of laboratory infrastructure 
and services to strengthen surveillance, would enable appropriate 
prescribing. Education, evidence­based guidelines and task shifting 
to allow safe, appropriate non­physician­based prescribing would 
improve access to appropriately prescribed antimicrobials to all 
in need, and removal of perverse incentives to over­prescribe, 
such as remuneration linked to prescription, would disincentivise 
inappropriate prescribing.
The lack of new drugs to treat bacteria containing NDM­1, KPC 
and other multidrug­resistant mutations is having significant effects 
on patient morbidity and mortality.[6­7] For many such infections we 
now rely on colistin, a drug developed in the 1960s with significant 
renal toxicity, as the last line of defence. The increasing reports of 
colistin resistance, including in our own country, herald our entry 
into the post­antibiotic era.[8,9] With no new antibacterials expected 
for multidrug­resistant Gram­negative bacteria in the next 10 ­ 15 
years based on current models, we need to preserve what we have, 
and reinvigorate the antibacterial drug pipeline. To enable this, 
new models of antimicrobial research and development (R&D), 
and pricing that de­links profit from volume of sales, are required, 
and a combination of push­and­pull mechanisms, private­public 
partnerships and other innovative models that can serve as incentives 
for R&D should be explored.
AMR in the SA context needs to take into account a range of 
infections. Extensively and totally drug­resistant tuberculosis (TB) 
is spreading in the country;[10] approximately half of all non­albicans 
candida infections are resistant to fluconazole;[11] current rates of 
transmitted resistance to first­line antiretrovirals in HIV are ~5%, yet 
as antiretroviral roll­out continues, resistance rates are set to rise to 
10 ­ 17%;[12] and hopes for the elimination of falciparum malaria are 
threatened by the risk of spread of artemesinin resistance from South­
East Asia.[13] A number of strategies are already in place for HIV, TB 
and malaria through established national working groups. In terms 
of antibacterial resistance, the national response has gathered pace 
since the publication of a situational analysis in 2011 by the Global 
Antibiotic Resistance Partnership­South Africa (GARP­SA).[14] The 
South African Antibiotic Stewardship Programme (SAASP)[15] has led 
the introduction of stewardship to promote appropriate antimicrobial 
prescribing across public and private health sectors, with positive 
results.[16] AMR working groups with co­ordinated activities have 
begun work in some provinces, and following meetings between the 
SAASP and the National Department of Health, work began on a 
national AMR strategy with widespread stakeholder involvement. 
This work has accelerated since the WHO resolution was proposed 
in January 2014. The strategy rests on strengthening four pillars: 
governance, surveillance and reporting, antimicrobial stewardship 
(AMS), and infection prevention and control.
Recognising that AMR involves human and animal health, 
and requires co­ordinated collaboration with other key areas, an 
intersectoral Ministerial Advisory Committee is to be formed to advise 
the Minster of Health. The committee will include representation 
from the departments of Health, Agriculture, Forestry and Fisheries, 
Science and Technology, Trade and Industry, and Education, in 
addition to public and private health providers, academia, infection 
societies and other relevant stakeholders. National core standards for 
AMS and infection prevention control (IPC) are under consideration, 
which will direct governance at institutional and district levels. 
Strengthening of surveillance and reporting go beyond patterns of 
AMR to include antimicrobial use, drug quality and medication 
errors, all of which are important factors to optimise prescribing. 
A central, national body is needed to co­ordinate and warehouse 
all laboratory surveillance data, and both statutory and sentinel 
reporting notification systems are required to inform appropriate 
prescribing.
To strengthen AMS, we need to build expertise by integrating it 
into curricula for all healthcare professionals in training and making 
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it part of continuing professional development programmes. We need 
to institutionalise AMS so that it is incorporated into job descriptions 
and performance appraisals, and develop ‘champions’ in facilities 
and districts. At the coalface, the strategy is to integrate information 
technology systems so that pharmacy, microbiology and clinical 
information can be collated and drive appropriate prescribing. 
Adopting national core standards that require each institution and 
district to have an AMS committee and AMS team(s) will promote 
appropriate prescribing, as will a set of national guidelines, in line 
with the Essential Drugs List and structured treatment guidelines. 
For animal health, we need to phase out the use of antimicrobials 
where evidence exists that they select out for cross­resistance in 
humans. In addition, a co­ordinated programme of research and 
audit is required towards phasing out of antimicrobials used for 
animal growth promotion.
The strategy to strengthen IPC mirrors much of that for AMS 
in terms of education, clear governance structures, and integration 
with AMS team activities. Supporting the Expanded Program on 
Immunization to ensure that our children, high­risk adolescents 
and adults are vaccinated against bacterial and viral infections 
can reduce the need for antimicrobials in the first place. Creating 
the infrastructure and support systems to ensure proper airborne 
precautions to prevent Mycobacterium tuberculosis transmission, 
and contact precautions for bacterial infections other than TB, 
focusing on identification and isolation of patients, personal 
protective equipment and above all excellent hand hygiene practice, 
lie at the heart of the IPC strategy. Involving our patients by 
empowering them to remind health professionals to comply with 
hand hygiene and protective equipment is another valuable piece 
in the jigsaw.[17]
AMR is no longer someone else’s problem. It’s personal, it’s here 
to stay, and if we don’t do something about it now, our patients’ 
morbidity and mortality will increase substantially. It would be 
good not to hear anyone say ‘Nice resolution, shame about the 
action.’
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